Merck Sharp + Dohme Corp.

Orchid Pharma Ltd.

Hongwu Wang

Michael Berlin

Pauline C Ting

Xianhai Huang

Jinlong Jiang

Fa-Xiang Ding

Haifeng Tang

Wanying Sun

Yan Guo

Yeon-Hee Lim

Weiguo Liu

Andrew William Stamford

Tesfaye Biftu

Ravi P Nargund

Amjad Ali

Robert G Aslanian

Michael W Miller

Dong Xiao

Joseph Michael Kelly

Sheo B Singh

Younong Yu

Guoqing Li

Helen Y Chen

Rongze Kuang

Shuzhi Dong

Anthony K Ogawa

Tony Siu

Qiaolin Deng

Christopher W Plummer

Linda Brockunier

Wonsuk Chang

Junying Zheng

Quang T Truong

Weidong Pan

Min K Park

Heping Wu

Walter Won

Gang Zhou

Katherine Young

Yi Zang

Rudrajit Mal

Gopalan Balasubramanian

David Kim

Venkatesan Parameswaran

Reynalda Keh Dejesus

Maneesh Paul-Satyaseela

Gioconda V Gallo-Etienne

Craig A Parish

Hariharan Periasamy

Venkateshwarlu Jakkala

Anne Mai Wassermann

Chidambaram Venkateswaran Srinivasan

Sridhar Ramanathan Iyer

Bharani Thirunavukkarasu

Prabhakar Rao Gunturu

Manjula Devi Deshkumar

Min Park

Michael Miller

Jinlong Jian

This invention provides compositions, compounds, and uses thereof, wherein said compounds comprise a single strand oligonucleotide that may form a short oligonucleotide hairpin or stem loop molecule with self complementary base pairing of less than 12 base pairs that bind to RIG-I and activate the RIG-I pathway.

Substituted RIG-I agonists: compositions and methods thereof

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof: wherein: 'Z' and Rare defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease. 

Substituted imidazo[1,2-c]quinazolines as A2A antagonists

The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A, Q, A, M, W, Rand Rare as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

Biaryl monobactam compounds and methods of use thereof for the treatment of bacterial infections

This invention relates to carbapenem compounds of the following formula: wherein A, Z, X, R, and Rare as described herein, as well as stereoisomers, pharmaceutically acceptable salts or N-oxides thereof, which may be useful for the treatment of bacterial infections, particularly drug-resistant bacterial infections, as well as the processes for the preparation of compounds, the pharmaceutical compositions of these compounds and their use in the treatment of bacterial infection.

Substituted carbapenems for the treatment of bacterial infections

Disclosed are compounds having the structure of Formula I, or a pharmaceutically acceptable salt of any thereof, wherein: 'Z', Rand Rare defined herein, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease. 

Aminopyrazine compounds with A2A antagonist properties

Disclosed are compounds of Formula A and Formula A-1, or a salt thereof, and pharmaceutical formulations (pharmaceutical compositions) comprising those compounds, or a salt thereof; wherein 'R', 'R', &#x201c;R&#x201d;, &#x201c;R&#x201d;, and &#x201c;Het&#x201d; are defined herein above, which compounds are believed suitable for use in selectively antagonizing the A2a receptors, for example, those found in high density in the basal ganglia. Such compounds and pharmaceutical formulations are believed to be useful in treatment or management of neurodegenerative diseases, for example, Parkinson's disease, or movement disorders arising from use of certain medications used in the treatment or management of Parkinson's disease. 

The present invention relates to bicyclic aryl monobactam compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein A, L, M, W, X, Y, Z, Rand Rare as defined herein. The present invention also relates to compositions which comprise a bicyclic aryl monobactam compound of the invention or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of one or more beta-lactamase inhibitor compounds. 

Bicyclic aryl monobactam compounds and methods of use thereof for the treatment of bacterial infections

Growing community of inventors

Westfield, NJ, United States of America

Hongwu Wang